Company intelligence / Profile preview

Christine Leonard

Huntington, New York, United Statesleonardstories.com ↗

Ownership: Private
Development stage: Other

Overview

Sen-Jam Pharmaceutical has completed enrollment for its Phase 2 trial of SJP‑002C for upper respiratory infections, including COVID, in partnership with Duke University. The company’s lead asset, SJP‑001 for alcohol hangover prevention, has also advanced to Phase 2 with support from investors like 5 Horizons Capital. Early data suggest the PAIR platform offers rapid anti-inflammatory effects with potential applications across multiple acute and chronic inflammatory conditions.

Therapeutic areas: PsychiatryMetabolic DisordersInfectious DiseasesOther
Modalities: Small moleculePlatform technology (PAIR)
Industry: Consulting

Partnerships

NovotechDuke UniversityDestum Partners

Beyond the preview

Go deeper on Christine Leonard.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Christine Leonard.

Explore the full profile